MERCAPTO-MODIFIED BIOCOMPATIBLE MACROMOLECULE DERIVATIVES WITH LOW DEGREE OF MERCAPTO-MODIFICATION AND THE CROSS-LINKED MATERIALS AND USES THEREOF

摘要

The present invention discloses a mercapto-modified biocompatible macromolecule derivative with a low degree of modification. The mercapto-modified biocompatible macromolecule derivative not only maintains the initial structure, physiological function and biocompatibility as much as possible, but also allows the preparation of the biocompatible macromolecule cross-linked material with a low degree of cross-linking through the effectively chemical cross-linking with the introduced mercapto group. The present invention further discloses a disulfide-bond cross-linked biocompatible macromolecule material with a very low degree of cross-linking. The disulfide-bond cross-linked biocompatible macromolecule material not only maintains the initial structure, physiological function and biocompatibility of the biocompatible macromolecule as much as possible, but also effectively prolongs turn over and reduces the solubility of the biocompatible macromolecule in vivo, better meeting the requirements of various clinical applications. The present invention further relates to the application of the disulfide-bond cross-linked biocompatible macromolecule material in the field of medicine and pharmacy.

主权项

1. A disulfide-bond cross-linked biocompatible macromolecule material comprising one or more of a mercapto-modified biocompatible macromolecule derivative with a low degree of mercapto-modification, wherein the mercapto-modified biocompatible macromolecule derivative comprises:
at least three mercapto groups in its side chain and having a degree of mercapto-modification of ≦4.5%; wherein the mercapto-modified biocompatible macromolecule derivative is obtained by chemically introducing the mercapto group into the side-chain group of the biocompatible macromolecule; and further wherein the degree of mercapto-modification is a percentage of an amount of the introduced mercapto group in an amount of available side-chain group of the biocompatible macromolecule for modification; and further wherein the biocompatible macromolecule is chondroitin sulfate or hyaluronic acid, or the salts and derivatives thereof.